Novartis's bid for Excellergy under review in Australia
MLex Summary: Novartis' proposal to acquire 100 percent of the issued and outstanding capital stock of US‑based biotech Excellergy will be reviewed by Australia's competition watchdog. In a statement Tuesday, the Australian Competition...To view the full article, register now.
Already a subscriber? Click here to view full article